
ARCE Therapeutics, a Taiwan based biotech company, specializes in developing proprietary gene-modified cellular immunotherapies. ARCE’s CAR-T/NK cell therapy products are developed via three technologies, DashCAR®, MaxCAR®, and OneCAR®, for CAR immune cell therapy with high efficacy, safety, and durability, and thus to achieve a sustained improved response capable of conquering human diseases.
Annual Revenue$10M to $25M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.